BiotechTube

REL-1017 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Jan 8, 2021 → Nov 10, 2022

NCT ID
NCT04688164

About REL-1017 + Placebo

REL-1017 + Placebo is a phase 3 stage product being developed by Relmada Therapeutics for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04688164. Target conditions include Major Depressive Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (5)

NCT IDPhaseStatus
NCT05081167Phase 3Completed
NCT04688164Phase 3Completed
NCT03051256Phase 2Completed
NCT03638869Phase 1Completed
NCT03637361Phase 1Completed

Competing Products

20 competing products in Major Depressive Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77

Other Products from Relmada Therapeutics

REL-1017 + PlaceboPhase 3
69
NDV-01 (sustained-release gemcitabine-docetaxel)Phase 3
69
NDV-01 (sustained-release gemcitabine-docetaxel)Phase 3
69
NDV-01 (sustained-release gemcitabine-docetaxel)Phase 3
69
REL-1017Phase 3
69